Arch Ev To Sales vs Price To Sales Ratio Analysis

ARCH Stock

CAD 1.96 0.04 2.08%

Arch Biopartners financial indicator trend analysis is way more than just evaluating Arch Biopartners prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arch Biopartners is a good investment. Please check the relationship between Arch Biopartners Ev To Sales and its Price To Sales Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arch Biopartners. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Ev To Sales vs Price To Sales Ratio

Ev To Sales vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arch Biopartners Ev To Sales account and Price To Sales Ratio. At this time, the significance of the direction appears to have totally related.

The correlation between Arch Biopartners' Ev To Sales and Price To Sales Ratio is 1.0. Overlapping area represents the amount of variation of Ev To Sales that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Arch Biopartners, assuming nothing else is changed. The correlation between historical values of Arch Biopartners' Ev To Sales and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Sales of Arch Biopartners are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Ev To Sales i.e., Arch Biopartners' Ev To Sales and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Arch Biopartners stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Arch Biopartners sales, a figure that is much harder to manipulate than other Arch Biopartners multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Arch Biopartners' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arch Biopartners current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arch Biopartners. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Selling General Administrative is likely to climb to about 763.7 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 109.4 K in 2024.

	2021	2022	2023	2024 (projected)
Research Development	1.3M	2.2M	2.5M	2.7M
Interest Expense	309.3K	358.9K	412.8K	433.4K

Research Development Interest Expense

Arch Biopartners fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Term Investments	Short Long Term Debt Total	Net Receivables	Short Term Debt	Non Current Liabilities Total	Inventory	Common Stock	Long Term Investments	Short Long Term Debt	Net Tangible Assets
Total Assets		0.32	0.45	-0.57	0.15	0.66	-0.6	0.73	0.45	0.45	0.36	0.03	0.56	0.64	0.94	-0.13	0.58	0.65	0.92	0.4	0.59	0.26	0.55	-0.05	0.4	-0.61
Other Current Liab	0.32		0.2	-0.27	0.03	0.3	-0.17	0.29	-0.04	-0.04	0.01	0.02	0.16	0.27	0.3	-0.03	0.19	0.28	0.4	0.11	0.32	0.78	0.08	-0.01	0.11	-0.27
Total Current Liabilities	0.45	0.2		-0.85	0.27	0.87	-0.79	0.36	0.8	0.8	0.3	0.02	0.84	0.91	0.65	-0.22	0.69	0.89	0.32	0.95	0.14	0.49	0.63	-0.75	0.95	-0.78
Total Stockholder Equity	-0.57	-0.27	-0.85		-0.33	-0.97	0.97	-0.69	-0.77	-0.77	-0.5	-0.25	-0.92	-0.97	-0.69	0.3	-0.9	-0.97	-0.39	-0.88	-0.58	-0.43	-0.82	0.46	-0.88	0.99
Property Plant And Equipment Net	0.15	0.03	0.27	-0.33		0.32	-0.49	0.13	0.44	0.44	0.9	0.12	0.03	0.32	0.31	-0.99	0.31	0.34	0.12	0.34	0.24	-0.25	0.72	-0.18	0.3	-0.32
Net Debt	0.66	0.3	0.87	-0.97	0.32		-0.94	0.7	0.76	0.76	0.46	0.23	0.91	0.99	0.8	-0.29	0.9	1.0	0.53	0.88	0.59	0.44	0.78	-0.55	0.88	-0.96
Retained Earnings	-0.6	-0.17	-0.79	0.97	-0.49	-0.94		-0.69	-0.8	-0.8	-0.66	-0.21	-0.87	-0.94	-0.72	0.47	-0.9	-0.94	-0.41	-0.85	-0.61	-0.26	-0.91	0.4	-0.84	0.97
Accounts Payable	0.73	0.29	0.36	-0.69	0.13	0.7	-0.69		0.42	0.42	0.35	0.17	0.66	0.68	0.71	-0.12	0.69	0.68	0.64	0.39	0.88	0.28	0.58	-0.08	0.39	-0.77
Cash	0.45	-0.04	0.8	-0.77	0.44	0.76	-0.8	0.42		1.0	0.48	0.13	0.74	0.82	0.64	-0.4	0.78	0.81	0.19	0.87	0.33	0.17	0.72	-0.62	0.87	-0.73
Cash And Short Term Investments	0.45	-0.04	0.8	-0.77	0.44	0.76	-0.8	0.42	1.0		0.48	0.13	0.74	0.82	0.64	-0.4	0.78	0.81	0.19	0.87	0.33	0.17	0.72	-0.62	0.87	-0.73
Common Stock Shares Outstanding	0.36	0.01	0.3	-0.5	0.9	0.46	-0.66	0.35	0.48	0.48		0.2	0.23	0.44	0.42	-0.87	0.48	0.47	0.24	0.39	0.42	-0.21	0.89	0.01	0.36	-0.51
Other Current Assets	0.03	0.02	0.02	-0.25	0.12	0.23	-0.21	0.17	0.13	0.13	0.2		0.14	0.2	0.05	-0.12	0.37	0.22	-0.02	0.19	0.43	-0.26	0.19	-0.02	0.19	-0.25
Other Stockholder Equity	0.56	0.16	0.84	-0.92	0.03	0.91	-0.87	0.66	0.74	0.74	0.23	0.14		0.92	0.66	0.0	0.87	0.91	0.37	0.87	0.47	0.45	0.63	-0.51	0.88	-0.91
Total Liab	0.64	0.27	0.91	-0.97	0.32	0.99	-0.94	0.68	0.82	0.82	0.44	0.2	0.92		0.8	-0.29	0.89	1.0	0.49	0.92	0.54	0.44	0.77	-0.61	0.92	-0.95
Total Current Assets	0.94	0.3	0.65	-0.69	0.31	0.8	-0.72	0.71	0.64	0.64	0.42	0.05	0.66	0.8		-0.29	0.69	0.8	0.87	0.61	0.57	0.28	0.64	-0.37	0.61	-0.7
Intangible Assets	-0.13	-0.03	-0.22	0.3	-0.99	-0.29	0.47	-0.12	-0.4	-0.4	-0.87	-0.12	0.0	-0.29	-0.29		-0.29	-0.31	-0.12	-0.3	-0.26	0.27	-0.68	0.16	-0.26	0.29
Short Term Investments	0.58	0.19	0.69	-0.9	0.31	0.9	-0.9	0.69	0.78	0.78	0.48	0.37	0.87	0.89	0.69	-0.29		0.91	0.39	0.83	0.71	0.23	0.77	-0.45	0.83	-0.9
Short Long Term Debt Total	0.65	0.28	0.89	-0.97	0.34	1.0	-0.94	0.68	0.81	0.81	0.47	0.22	0.91	1.0	0.8	-0.31	0.91		0.5	0.91	0.57	0.43	0.79	-0.58	0.9	-0.96
Net Receivables	0.92	0.4	0.32	-0.39	0.12	0.53	-0.41	0.64	0.19	0.19	0.24	-0.02	0.37	0.49	0.87	-0.12	0.39	0.5		0.22	0.52	0.25	0.37	-0.06	0.22	-0.43
Short Term Debt	0.4	0.11	0.95	-0.88	0.34	0.88	-0.85	0.39	0.87	0.87	0.39	0.19	0.87	0.92	0.61	-0.3	0.83	0.91	0.22		0.26	0.34	0.7	-0.74	1.0	-0.81
Non Current Liabilities Total	0.59	0.32	0.14	-0.58	0.24	0.59	-0.61	0.88	0.33	0.33	0.42	0.43	0.47	0.54	0.57	-0.26	0.71	0.57	0.52	0.26		0.09	0.54	0.02	0.25	-0.67
Inventory	0.26	0.78	0.49	-0.43	-0.25	0.44	-0.26	0.28	0.17	0.17	-0.21	-0.26	0.45	0.44	0.28	0.27	0.23	0.43	0.25	0.34	0.09		0.06	-0.26	0.36	-0.41
Common Stock	0.55	0.08	0.63	-0.82	0.72	0.78	-0.91	0.58	0.72	0.72	0.89	0.19	0.63	0.77	0.64	-0.68	0.77	0.79	0.37	0.7	0.54	0.06		-0.23	0.68	-0.82
Long Term Investments	-0.05	-0.01	-0.75	0.46	-0.18	-0.55	0.4	-0.08	-0.62	-0.62	0.01	-0.02	-0.51	-0.61	-0.37	0.16	-0.45	-0.58	-0.06	-0.74	0.02	-0.26	-0.23		-0.74	0.38
Short Long Term Debt	0.4	0.11	0.95	-0.88	0.3	0.88	-0.84	0.39	0.87	0.87	0.36	0.19	0.88	0.92	0.61	-0.26	0.83	0.9	0.22	1.0	0.25	0.36	0.68	-0.74		-0.81
Net Tangible Assets	-0.61	-0.27	-0.78	0.99	-0.32	-0.96	0.97	-0.77	-0.73	-0.73	-0.51	-0.25	-0.91	-0.95	-0.7	0.29	-0.9	-0.96	-0.43	-0.81	-0.67	-0.41	-0.82	0.38	-0.81

Click cells to compare fundamentals

Arch Biopartners Account Relationship Matchups

Arch Biopartners fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	741.3K	2.7M	621.6K	1.2M	1.1M	588.8K
Other Current Liab	269.8K	424.8K	190K	172.5K	155.3K	160.5K
Total Current Liabilities	1.2M	3.2M	2.8M	6.0M	6.9M	7.2M
Total Stockholder Equity	(3.9M)	(3.9M)	(4.5M)	(5.5M)	(5.0M)	(4.7M)
Net Debt	2.7M	4.7M	3.9M	4.2M	4.8M	5.1M
Retained Earnings	(22.1M)	(23.3M)	(24.7M)	(28.1M)	(25.2M)	(24.0M)
Accounts Payable	949.2K	962.0K	489.4K	393.4K	452.4K	410.7K
Cash	653.7K	448.2K	506.3K	831.3K	956.0K	1.0M
Cash And Short Term Investments	653.7K	448.2K	506.3K	831.3K	956.0K	1.0M
Common Stock Shares Outstanding	59.9M	61.3M	62.2M	62.5M	71.8M	41.8M
Liabilities And Stockholders Equity	741.3K	2.7M	621.6K	1.2M	1.1M	588.8K
Other Current Assets	26.6K	19.3K	28.1K	43.0K	49.5K	39.8K
Other Stockholder Equity	4.6M	4.7M	4.7M	6.7M	6.0M	6.3M
Total Liab	4.6M	6.6M	5.1M	6.7M	7.7M	8.1M
Total Current Assets	741.3K	2.7M	621.6K	1.2M	1.3M	1.4M
Short Long Term Debt Total	3.4M	5.2M	4.4M	5.0M	5.8M	6.1M
Net Receivables	61.0K	2.2M	87.2K	296.9K	341.4K	337.1K
Non Current Liabilities Total	3.4M	3.4M	2.3M	703.9K	809.5K	1.3M
Common Stock	13.7M	14.8M	15.6M	15.9M	18.3M	11.4M
Net Tangible Assets	(2.6M)	(3.9M)	(3.9M)	(4.5M)	(4.0M)	(3.8M)
Long Term Debt	3.4M	3.4M	2.3M	703.9K	809.5K	769.0K
Net Invested Capital	(477.7K)	1.3M	(57.8K)	(493.6K)	(444.3K)	(422.1K)
Net Working Capital	(477.7K)	(520.8K)	(2.2M)	(4.8M)	(4.3M)	(4.1M)
Capital Stock	13.7M	14.8M	15.6M	15.9M	18.3M	15.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arch Stock Analysis

When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC